Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus PYLARIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus PYLARIFY.
MACROTEC vs PYLARIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. It allows for positron emission tomography (PET) imaging of PSMA-positive lesions.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
1 mg/kg IV bolus administered once.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life of approximately 12.3 hours (range 8-18 hours), supporting once-daily dosing in clinical practice.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal (approximately 99% of administered dose as unchanged drug) and fecal (<1%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical